CSIMarket
 
Prolung Inc   (FRES)
Other Ticker:  
 
 
Price: $2.0550 $-0.35 -14.375%
Day's High: $2.4 Week Perf: -22.45 %
Day's Low: $ 2.06 30 Day Perf: 545.21 %
Volume (M): 10 52 Wk High: $ 3.93
Volume (M$): $ 20 52 Wk Avg: $1.06
Open: $2.15 52 Wk Low: $0.27



 Market Capitalization (Millions $) 9
 Shares Outstanding (Millions) 5
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -3
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 0

Prolung Inc
Prolung Inc is a medical technology company that develops and manufactures innovative respiratory support systems. Their products are designed to provide longer-lasting respiratory support and improved quality of life for patients who suffer from chronic lung diseases such as chronic obstructive pulmonary disease (COPD) and cystic fibrosis. Prolung's devices are non-invasive, portable, and easy to use, making them suitable for both hospital and home settings. The company is dedicated to advancing respiratory care and improving patient outcomes through their cutting-edge technologies.


   Company Address: 350 W. 800 N. Salt Lake City 84103 UT
   Company Phone Number: 736?0729   Stock Exchange / Ticker: FRES
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Announcement

Fresh2 Group Ltd. Transforms Share Structure, Paving the Way for a Lucrative Future in the Food Industry ...

Published Mon, Jun 24 2024 9:14 PM UTC

Currently, Fresh2's ADS structure stands at one (1) ADS representing twenty (20) Class A ordinary shares. However, the Company plans to implement a transformative ADS Ratio Change, whereby each ADS will represent two hundred (200) Class A ordinary shares. This significant increase in the ADS Ratio will revolutionize the Company's share structure, maximizing shareholder value...

Prolung Inc

Prolung Inc. Unveils Unexpected Q1 2023 Earnings Results in Laboratory Analytical Instruments Industry Amidst Operating Deficit

As a cautious investor, it is important to take heed of the laboratory analytical instruments sector's first quarter earnings report for 2023. The operating deficit of $-0.568664 million for the period of January to March 2023 is a cause for concern, especially given that the company has not released any top-line figures thus far. This represents an increase compared to the first quarter of 2022, where the operating deficit was $-1.430521 million.
It is important to note that the operating deficit is a vital indicator for the course of the company. As corporations like FRES continue to develop revenue streams, it is crucial for them to operate cost-effectively to attain another level. The encouraging news is that the diminishing returns have decreased to $-0.809 million, from $-1.761 million in the first quarter of 2022, which may benefit the organization on its course to be a doyen in the industry.






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com